| 证券代码 | MNK.N |
| 证券名称 | Mallinckrodt plc |
| 证券类型 | 美股 |
| 上市场所 | 纽约证券交易所 |
| 上市板块 | - |
| 发行方式 | - |
| 首发上市日 | 2013-07-01 |
| 首发价格(元) | - |
| 首发数量(股) | 0 |
| 首发募资额(元) | - |
| 首发主承销商 | - |
| 货币单位 | USD |
| 公司名称 | Mallinckrodt public limited company |
| 注册地址 | 爱尔兰共和国 |
| 办公地址 | 3 Lotus Park, The Causeway, Staines-Upon-Thames, Surrey, United Kingdom |
| 成立日期 | 2013-01-09 |
| 董事会主席 | - |
| 公司属地 | Ireland 爱尔兰共和国 |
| 公司网址 | www.mallinckrodt.com |
| 电话 | +44 (017) 8463-6700 |
| 传真 | - |
| 公司简介 | Mallinckrodt public limited company is a global business that develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. Therapeutic areas of focus include autoimmune and rare disease specialty areas (including neurology, rheumatology, nephrology, ophthalmology and pulmonology);immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products; and central nervous system drugs. It operates its business in two reportable segments: Specialty Brands produces and markets branded pharmaceutical products and therapies; and Specialty Generics produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredients ("API") consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. |